ACCESS-IS
Access-IS, part of HID, the leading supplier of software agnostic ticket validators is excited to announce the integration of its VAL100 devices by Masabi. The integration is part of Masabi’s My Fare solution, a contactless mobile ticketing app for Calgary Transit that lets passengers buy tickets and passes anytime, anywhere, using their smartphones. It’s fast, easy, contactless and a safe way to pay and ride transit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005015/en/
The My Fare app, which is powered by Masabi’s Justride platform and can be downloaded from the App Store and Google Play, allows riders of Calgary Transit services to purchase and use fare products such as regular monthly and day passes, airport boarding pass, and single ride tickets directly from their mobile device.
As part of the project over 1000 Access-IS VAL100 ticket validators have been installed across the bus network covering 155 routes. Passengers scan their dynamic and encrypted mobile passes on the devices when boarding the bus, with an audible beep and a colored screen identifying the ticket as valid for use. These validation units will help speed up boarding times making riding Calgary Transit services faster and safer by enabling contactless fare payment and validation. The validation units are powered by Masabi’s Justride Inspect software but also read NFC and contactless EMV (cEMV) technology, giving the agency the flexibility to turn on Account-Based Ticketing and other account-based tokens, if required.
“Calgarians, like citizens in towns and cities around the world, are using smartphones in almost all aspects of their day and made offering the option for riders to use their phone instead of a paper ticket a logical step for Calgary Transit,” said Brian Zanghi, CEO of Masabi. “The change in people’s behaviour brought about by the current requirement for social distancing has made mobile ticketing and the move towards a more contactless journey experience a must-have for transit agencies.”
The VAL100 combines barcode and NFC/RFID reading functionality to provide a single point of presentation for tickets and travel passes – whether presented on a paper ticket, smartcard or mobile phone. It is also available with EMV Level 2 certification, allowing for applications where contactless payments are required. It offers PCI and SRED compliance for contactless payments using VISA, MasterCard, AMEX and Discover payment schemes. It features clear visual and audio passenger feedback, a robust design and a wide range of connection options for installation flexibility.
Speaking about the installation, Bryan Cunningham Regional Sales Manager (Americas) at Access-IS said “It’s always a pleasure to work with Masabi to deliver a ticketing and fare payment solution focused on providing the very best passenger experience whilst protecting the transits agency’s ability to manage fare revenue.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom